Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 2
2008 1
2009 1
2011 1
2012 1
2013 2
2015 2
2017 1
2018 1
2022 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
The following term was not found in PubMed: /
Page 1
Adjusting oral oxybutynin medication for hyperhidrosis to reflect seasonal temperature variations.
Del Boz J, Millán-Cayetano JF, García-Montero P, García-Harana C, Rivas-Ruiz F, de Troya-Martín M. Del Boz J, et al. Dermatol Ther. 2018 Jul;31(4):e12615. doi: 10.1111/dth.12615. Epub 2018 May 8. Dermatol Ther. 2018. PMID: 29740900
Most studies of oral oxybutynin (OOx) for the treatment of hyperhidrosis (HH) have assumed a stable treatment protocol, without taking into account adverse effects (AE) or seasonal variations in temperature. ...Given that the possible AE of OOx are dose-depen …
Most studies of oral oxybutynin (OOx) for the treatment of hyperhidrosis (HH) have assumed a stable treatment protocol, without takin …
Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system.
Todorova A, Vonderheid-Guth B, Dimpfel W. Todorova A, et al. J Clin Pharmacol. 2001 Jun;41(6):636-44. doi: 10.1177/00912700122010528. J Clin Pharmacol. 2001. PMID: 11402632 Clinical Trial.

Isolated power decreases were only observed in the theta frequency band. In contrast, oxybutynin caused significant power reductions in four frequency bands (theta, alpha 1, alpha 2, and beta 1; p < 0.01). The subjectively evaluated drug tolerability was comparable betw

…
Isolated power decreases were only observed in the theta frequency band. In contrast, oxybutynin caused significant power reductions …
Trospium chloride and oxybutynin hydrochloride in a german study of adults with urinary urge incontinence: results of a 12-week, multicenter, randomized, double-blind, parallel-group, flexible-dose noninferiority trial.
Zellner M, Madersbacher H, Palmtag H, Stöhrer M, Bödeker RH; P195 Study Group. Zellner M, et al. Clin Ther. 2009 Nov;31(11):2519-39. doi: 10.1016/j.clinthera.2009.11.005. Clin Ther. 2009. PMID: 20109997 Clinical Trial.
RESULTS: Of the 1658 patients treated, 828 patients (49.9%) received trospium 45 mg/d and 830 patients (50.1%) received oxybutynin 7.5 mg/d. After 4 weeks, daily doses were doubled in 29.2% (242/828) of patients in the trospium chloride group, and in 23.3% (193/830) of pat …
RESULTS: Of the 1658 patients treated, 828 patients (49.9%) received trospium 45 mg/d and 830 patients (50.1%) received oxybutynin 7. …
A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder.
Novara G, Galfano A, Secco S, D'Elia C, Cavalleri S, Ficarra V, Artibani W. Novara G, et al. Eur Urol. 2008 Oct;54(4):740-63. doi: 10.1016/j.eururo.2008.06.080. Epub 2008 Jul 9. Eur Urol. 2008. PMID: 18632201
Tolterodine immediate release (IR) had a more favorable profile of adverse events than oxybutynin IR. Regarding different dosages of IR formulations, dose escalation might yield some limited improvements in the efficacy but at the cost of significant increase in the rate o …
Tolterodine immediate release (IR) had a more favorable profile of adverse events than oxybutynin IR. Regarding different dosages of …
Antimuscarinics for neurogenic overactive bladder in multiple sclerosis: real-life data.
Andretta E, Finazzi Agrò E, Calabrese M, Orecchia L, Furlan A, Zuliani C. Andretta E, et al. Ther Adv Urol. 2022 Sep 24;14:17562872221122484. doi: 10.1177/17562872221122484. eCollection 2022 Jan-Dec. Ther Adv Urol. 2022. PMID: 36172491 Free PMC article.

RESULTS: Significant reduction (p < 0.001) of mean PPIUS and pads use were detected, as well as a significant increase (p < 0.001) of PVR (143 42 ml).AEs, recorded in 53% of patients, were frequently multiple and caused suspension of AM in 10% of cases, mainly for xerosto

…

RESULTS: Significant reduction (p < 0.001) of mean PPIUS and pads use were detected, as well as a significant increase (p < 0.001) of

…
Efficacy and safety of oxybutynin topical gel 3% in patients with urgency and/or mixed urinary incontinence: a randomized, double-blind, placebo-controlled study.
Goldfischer ER, Sand PK, Thomas H, Peters-Gee J. Goldfischer ER, et al. Neurourol Urodyn. 2015 Jan;34(1):37-43. doi: 10.1002/nau.22504. Epub 2013 Oct 16. Neurourol Urodyn. 2015. PMID: 24133005 Clinical Trial.
AIMS: To assess the efficacy and safety of oxybutynin transdermal gel 3% (OTG3%), with propylene glycol for enhanced skin permeation, in patients with urinary incontinence (UI). ...Dry mouth, the most common treatment-related AE, occurred more often with OTG3% 84 mg …
AIMS: To assess the efficacy and safety of oxybutynin transdermal gel 3% (OTG3%), with propylene glycol for enhanced skin permeation, …
Pharmacokinetics of intravesical versus oral oxybutynin in healthy adults: results of an open label, randomized, prospective clinical study.
Krause P, Fuhr U, Schnitker J, Albrecht U, Stein R, Rubenwolf P. Krause P, et al. J Urol. 2013 Nov;190(5):1791-7. doi: 10.1016/j.juro.2013.05.011. Epub 2013 May 10. J Urol. 2013. PMID: 23669567 Clinical Trial.
In periods 1 and 2 subjects received a single dose of 10 mg oxybutynin HCl solution intravesically or a 5 mg tablet orally. Period 3 comprised repeat intravesical applications (7 doses) of 10 mg oxybutynin HCl. Enantioselective concentrations of oxybutynin an …
In periods 1 and 2 subjects received a single dose of 10 mg oxybutynin HCl solution intravesically or a 5 mg tablet orally. Period 3 …
Prescription pattern of oxybutynin ER in patients with overactive bladder in real life practice: a multicentre, open-label, prospective observational study.
Yoo DS, Han JY, Lee KS, Choo MS. Yoo DS, et al. Int J Clin Pract. 2012 Feb;66(2):132-8. doi: 10.1111/j.1742-1241.2011.02838.x. Epub 2011 Dec 20. Int J Clin Pract. 2012. PMID: 22188444
CONCLUSIONS: Most patients were prescribed 5-10 mg/day oxybutynin ER as both starting and maintenance doses, with a dose escalation rate of only 14.9%. Prescription of > 10 mg/day oxybutynin ER was not frequent in real life practice....
CONCLUSIONS: Most patients were prescribed 5-10 mg/day oxybutynin ER as both starting and maintenance doses, with a dose escalation r …
Efficacy and Adherence of Flexibly Adding on a Second Antimuscarinic Agent for Patients with Refractory Overactive Bladder.
Wang CC, Jiang YH, Kuo HC. Wang CC, et al. Low Urin Tract Symptoms. 2017 Jan;9(1):27-32. doi: 10.1111/luts.12103. Epub 2015 Jul 2. Low Urin Tract Symptoms. 2017. PMID: 28120445 Clinical Trial.
OBJECTIVES: To evaluate the efficacy and adverse events (AE) of flexibly adding on oxybutynin ER in patients with overactive bladder (OAB) refractory to monotherapy with the first muscarinic antagonist. ...At baseline, weeks 4, and 12 after the oxybutynin ER …
OBJECTIVES: To evaluate the efficacy and adverse events (AE) of flexibly adding on oxybutynin ER in patients with overactive b …
Comparison of the inhibitory effects of cromakalim and pinacidil (potassium channel openers) with those of oxybutynin on stimulated guinea pig and rabbit detrusor muscle strips.
Rizk DE, Arafat K, El-Sharkawy TY. Rizk DE, et al. Arch Gynecol Obstet. 2001 Aug;265(3):141-7. doi: 10.1007/s004040000150. Arch Gynecol Obstet. 2001. PMID: 11561743
To compare the inhibitory effects of a new group of smooth muscle relaxants, the potassium channel openers cromakalim and pinacidil, with those of oxybutynin on detrusor muscle stimulation in animals. Detrusor strips of guinea pigs (n=16) and rabbits (n=20) were mounted in …
To compare the inhibitory effects of a new group of smooth muscle relaxants, the potassium channel openers cromakalim and pinacidil, with th …